Written for: Patients, Caregivers, and Healthcare Professionals
Overview
Invasive Lobular Carcinoma (ILC) is the second most common histological subtype of invasive breast cancer, accounting for approximately 10–15% of all invasive breast carcinomas. Unlike the more prevalent Invasive Ductal Carcinoma (IDC), which originates in the milk ducts, ILC arises from the lobules—the milk-producing glands of the breast—and invades the surrounding stromal tissue in a distinctive single-file pattern.
ILC possesses unique biological, imaging, and clinical characteristics that distinguish it from IDC. It is frequently diagnosed at a larger size and more advanced stage due to its subtle radiographic appearance and lack of a palpable discrete mass in early stages. Understanding these nuances is critical for timely diagnosis, appropriate surgical planning, and optimal long-term management.
Epidemiology and Risk Factors
| Feature | Details |
|---|---|
| Incidence | ~10–15% of all invasive breast cancers; rising incidence noted in postmenopausal women. |
| Median Age at Diagnosis | Early 60s (slightly older than IDC). |
| Gender | Overwhelmingly female (<1% male). |
| Laterality | Higher rate of bilaterality (synchronous or metachronous) compared to IDC (~5–10% synchronous). |
| Multifocality/Multicentricity | High prevalence (20–40%), often requiring MRI for staging. |
Key Risk Factors
- Hormonal Exposure: Strong association with Estrogen Receptor (ER) positivity. Use of combined Hormone Replacement Therapy (HRT)—specifically estrogen plus progestin—is a more potent risk factor for ILC than for IDC.
- Reproductive History: Late age at first full-term pregnancy, nulliparity, early menarche, late menopause.
- Genetics: CDH1 germline mutations (Hereditary Diffuse Gastric Cancer syndrome) confer a lifetime breast cancer risk of 40–55%, predominantly ILC. BRCA2 mutations also elevate risk, though BRCA1 is more linked to Triple Negative/IDC.
- Lobular Carcinoma In Situ (LCIS): Considered a non-obligate precursor and risk indicator; women with LCIS have an 8–10x increased risk of developing invasive cancer (ILC or IDC) in either breast.
Pathology: The “Single File” Signature
The histological hallmark of ILC is the loss of E-cadherin function, a transmembrane glycoprotein essential for cell-to-cell adhesion. This loss is typically caused by somatic mutations in the CDH1 gene (located on chromosome 16q) or promoter hypermethylation.
Histological Growth Patterns
Recognizing variants is crucial as they carry different prognostic implications.
| Variant | Morphology | Clinical Significance |
|---|---|---|
| Classic (NOS) | Small, uniform cells infiltrating stroma in single-file lines (“Indian files”) or concentric targetoid patterns around ducts. Minimal tubule formation. | Standard prognosis; highly hormone receptor positive. |
| Solid | Sheets of cells with little stroma; >50% solid growth. | Slightly higher grade; marginally increased risk of recurrence. |
| Alveolar | Cells grouped in clusters of 20+ within distended acini. | Similar to classic. |
| Tubulolobular | Mixed single-file and small tubule formation. | Behavior mimics classic ILC. |
| Pleomorphic | High nuclear grade, marked pleomorphism, prominent nucleoli, frequent necrosis. | Aggressive variant; higher Ki-67, higher HER2 positivity rate, worse prognosis. |
| Signet Ring Cell | >10% cells with intracytoplasmic mucin vacuoles pushing nucleus to periphery. | Rare; associated with higher stage at presentation; distinct metastatic pattern (peritoneal, gastric). |
| Histiocytoid | Cells resemble histiocytes (macrophages); abundant eosinophilic cytoplasm. | Diagnostic challenge (mimics metastatic melanoma/sarcoma); requires IHC confirmation. |
Immunohistochemical (IHC) Profile (Typical Classic ILC)
| Marker | Typical Result | Clinical Relevance |
|---|---|---|
| E-cadherin | Negative (loss of membranous staining) | Diagnostic gold standard; distinguishes from IDC (positive). |
| p120 Catenin | Cytoplasmic (vs. membranous in IDC) | Supportive diagnostic marker. |
| ER / PR | Strongly Positive (95%+ / 70%+) | Predicts excellent response to endocrine therapy. |
| HER2 | Negative (90–95%) | Classic ILC rarely HER2+; Pleomorphic variant may be HER2+. |
| Ki-67 | Low (<10–15%) | Indicates low proliferative index; luminal A biology. |
| GATA3 / Mammaglobin | Positive | Confirms mammary origin in metastatic workup. |
🔬 How Does It Look? (Imaging & Gross Pathology)
ILC is notoriously “mammographically occult” or subtle. Its growth pattern—linear infiltration through stroma without eliciting a strong desmoplastic reaction (scarring)—means it often fails to form a discrete, spiculated mass typical of IDC.
Mammography (2D & 3D Tomosynthesis)
- Sensitivity: Lower than IDC (approx. 57–81% vs 80–95% for IDC).
- Common Presentations:
- Asymmetric Density / Focal Asymmetry: The most frequent finding (40–60%). A subtle area of increased density without a distinct mass shape.
- Architectural Distortion: Subtle tethering or “pulling” of parenchyma toward the lesion, often without a central mass.
- Spiculated Mass: Less common than IDC; margins may be indistinct or “ill-defined” rather than classically spiculated.
- Calcifications: Rare (<10–15% of cases). When present, usually coarse/heterogeneous (associated with comedo necrosis in pleomorphic variant) rather than fine pleomorphic microcalcifications typical of DCIS/IDC.
- Tomosynthesis (3D Mammo): Improves detection rates by reducing superimposition, better characterizing architectural distortion, but still misses a significant minority.
Ultrasound (US)
- Sensitivity: Higher than mammography (~68–98%), often the modality that first identifies a correlate for a mammographic asymmetry.
- Typical Sonographic Features:
- Hypoechoic mass with angular, indistinct, or “spiculated” margins.
- Parallel orientation (wider-than-tall) – less specific than IDC.
- Posterior acoustic shadowing (common, due to Cooper’s ligament infiltration).
- “Pseudobenign” features: Occasionally presents as a gently lobulated, hypoechoic mass with few malignant features, mimicking fibroadenoma or complex cyst.
- Lack of posterior enhancement (unlike many IDC masses).
Magnetic Resonance Imaging (MRI) – The Staging Gold Standard
- Sensitivity: >95% (highest of all modalities).
- Appearance: Irregular, spiculated mass with heterogeneous internal enhancement and slow, persistent (Type 3) kinetic curve (typical of low-grade, highly vascularized tumors).
- Critical Utility:
- Local Staging: Defines true tumor extent (often 1.5–2x larger than mammo/US).
- Multifocality/Multicentricity: Detects additional ipsilateral foci missed by other imaging (changes surgical plan in ~15–25%).
- Contralateral Screening: Detects occult contralateral cancer in 3–5% of newly diagnosed patients.
Gross Pathology (Macroscopic)
- Appearance: Typically a firm, gritty, ill-defined, white/tan induration within the breast parenchyma.
- Lack of Encapsulation: Infiltrates diffusely; difficult to “shell out” or separate from normal tissue.
- Size Discrepancy: Macroscopic size often underestimates microscopic extent due to microscopic tentacles extending beyond the palpable/firm area.
- Pleomorphic Variant: May show areas of hemorrhage, necrosis, or cystic degeneration.
🩺 Symptoms: Clinical Presentation
ILC often presents differently than IDC due to its diffuse growth pattern and lack of a discrete, hard “lump” in early stages.
Primary Breast Symptoms
| Symptom | Frequency | Description / Clinical Pearl |
|---|---|---|
| Palpable “Thickening” or “Fullness” | Most Common (50–70%) | Not a discrete lump. Patients describe a vague “ridge,” “shelf,” or area of firmness, often in the upper outer quadrant. Best appreciated with flat palpation (finger pads) comparing bilateral breasts. |
| No Palpable Abnormality | 20–30% | Detected solely on screening imaging (mammogram asymmetry or MRI). |
| Skin Changes | <10% | Late sign. Peau d’orange (skin edema), tethering, dimpling, or retraction due to Cooper’s ligament invasion. Less common than IDC at presentation. |
| Nipple Changes | <5% | Retraction, deviation, or inversion (central or peripheral tumors involving subareolar ducts). |
| Breast Pain (Mastalgia) | 10–15% | Non-cyclical, localized discomfort; less common than IDC. |
| Axillary Lump | 10–20% | Palpable lymphadenopathy indicating nodal metastasis. |
Metastatic Presentation (De Novo Stage IV or Recurrence)
ILC has a distinct metastatic tropism compared to IDC. Clinicians must maintain a high index of suspicion for these sites:
| Metastatic Site | Frequency vs. IDC | Clinical Presentation |
|---|---|---|
| Gastrointestinal (GI) Tract | Significantly Higher (Stomach, small bowel, colon) | Abdominal pain, nausea, vomiting, linitis plastica (stomach wall thickening), GI bleeding, obstruction, malabsorption. Often mimics primary gastric cancer. |
| Gynecologic | Higher (Ovaries, uterus, endometrium, cervix) | Abnormal uterine bleeding, pelvic mass, ovarian cysts (Krukenberg tumors – signet ring variant), ascites. |
| Peritoneum / Retroperitoneum | Higher | Ascites, abdominal distension, hydronephrosis (ureteric obstruction), cachexia. |
| Meninges / Leptomeninges | Higher | Headaches, cranial nerve palsies, confusion, radiculopathy (spinal). |
| Bone | High (Similar to IDC) | Pain (spine, ribs, pelvis), pathologic fracture, hypercalcemia. Usually osteolytic or mixed. |
| Liver / Lung | Common | Hepatomegaly, elevated LFTs, dyspnea, pleural effusion, cough. |
| Soft Tissue / Skin | Uncommon | Subcutaneous nodules, chest wall recurrence. |
Clinical Alert: A patient with a history of ILC presenting with unexplained abdominal symptoms, gynecologic bleeding, or neurologic deficits** requires urgent investigation for metastatic disease, even years after “curative” treatment.
Diagnosis: The Triple Assessment
Diagnosis relies on the Triple Test: Clinical Examination + Imaging (Mammo/US/MRI) + Pathology (Core Biopsy). Concordance of all three is mandatory.
- Core Needle Biopsy (CNB): Standard of care. 14-gauge or larger. Fine Needle Aspiration (FNA) is insufficient (cannot distinguish invasive from in situ, cannot assess grade/HER2/ki67 reliably, architectural pattern lost).
- Image Guidance: Ultrasound-guided preferred if sonographic correlate exists. Stereotactic (Mammo-guided) or MRI-guided biopsy required for MRI-only or mammographic-only findings (asymmetry/distortion).
- Pathology Confirmation: Requires IHC panel (E-cadherin, p120, ER, PR, HER2, Ki-67).
- Clip Placement: Mandatory at biopsy site for future localization/surgical excision and radiation boost planning.
Staging Workup
Staging follows the AJCC 8th Edition (TNM) system, incorporating anatomical stage and prognostic stage (Grade, ER, PR, HER2).
| Test | Indication |
|---|---|
| Breast MRI | Standard for ALL new ILC diagnoses (local extent, multicentricity, contralateral). |
| CT Chest/Abdomen/Pelvis | Stage III (locally advanced), inflammatory features, or symptoms suggestive of Stage IV. |
| Bone Scan (or NaF PET/CT) | Stage III, elevated Alkaline Phosphatase, bone pain. |
| Brain MRI | Only if neurologic symptoms (routine screening not recommended for asymptomatic early stage). |
| PET/CT | Increasingly used for Stage III/IV; superior for detecting ILC metastases in peritoneum, GI tract, bone marrow. |
| Genetic Testing | Strongly recommended if: Diagnosed <50y, Triple Negative (rare in ILC), Bilateral, Family Hx Breast/Ovarian/Gastric/Prostate/Pancreatic, Personal Hx Gastric Cancer, Ashkenazi Jewish ancestry. Specifically test CDH1. |
Treatment Modalities
Treatment is multidisciplinary (Surgery, Radiation, Medical Oncology). Biology drives systemic therapy; Anatomy drives local therapy.
1. Surgical Management
- Breast-Conserving Surgery (BCS / Lumpectomy):
- Feasibility: Possible in ~60–70% initially, but re-excision rates are higher (20–40%) than IDC due to diffuse margins and multifocality.
- Margin Status: “No ink on tumor” (SSO/ASTRO consensus) applies to ILC. Wider margins (>2mm) do not improve local control.
- Localization: Wire, radioactive seed (RSL), magnetic seed (Magseed), or radar reflector (SAVI Scout) placed by radiologist pre-op.
- Specimen Imaging: Mandatory (specimen mammogram or intraoperative US) to confirm target excision.
- Mastectomy:
- Indications: Multicentric disease (2+ quadrants), diffuse microcalcifications, persistent positive margins after re-excision, large tumor:breast ratio, patient preference, CDH1 mutation carrier (risk-reducing bilateral).
- Nipple-Sparing Mastectomy (NSM): Oncologically safe in selected patients (tumor >2cm from nipple, no nipple involvement on MRI).
- Axillary Staging:
- cN0: Sentinel Lymph Node Biopsy (SLNB) standard. Note: ILC has higher rate of isolated tumor cells (ITCs) and micrometastases; SLNB detection via OSNA/RT-PCR or serial sectioning is vital.
- cN1+: Axillary Lymph Node Dissection (ALND) or Targeted Axillary Dissection (TAD) post-neoadjuvant.
2. Radiation Therapy (RT)
- Post-BCS: Whole Breast Irradiation (WBI) standard. Hypofractionated regimens (15–16 fractions) are standard of care. Tumor bed boost (10–16 Gy) recommended for most invasive cancers.
- Post-Mastectomy (PMRT): Indicated for pT3/T4, pN2+, positive margins. Strongly consider for pN1 (1–3 nodes) given ILC biology and locoregional recurrence patterns (internal mammary nodes).
- Regional Nodal Irradiation (RNI): Internal mammary (IMN) and supraclavicular (SCV) fields considered for pN1+ or central/medial tumors.
3. Systemic Therapy
Neoadjuvant (Pre-operative) Therapy
- Chemotherapy: Classic ILC has low pathologic Complete Response (pCR) rates (<5–10%) due to low proliferation (Ki-67). Lack of pCR does not equate to treatment failure. Neoadjuvant chemo primarily used for downstaging large tumors (cT3/T4) or node-positive disease to enable BCS or de-escalate axillary surgery.
- Neoadjuvant Endocrine Therapy (NET): Highly effective option for postmenopausal ER+ HER- ILC. 4–6 months of Aromatase Inhibitor (Letrozole/Anastrozole/Exemestane) achieves clinical response rates 50–70%, facilitating BCS without chemotherapy toxicity. Preferred for frail/elderly or strong Luminal A biology.
Adjuvant (Post-operative) Therapy
| Subtype | Standard Approach |
|---|---|
| ER+/HER2- (Luminal A-like) | Endocrine Therapy (ET) alone for 5–10 years. Chemotherapy generally omitted if low clinical risk (small, node-negative, low grade, low Ki-67, low genomic risk score). |
| ER+/HER2- (Luminal B-like / High Clinical Risk) | ET + Chemotherapy. Genomic assays (Oncotype DX, MammaPrint, Prosigna, EndoPredict) VALIDATED IN ILC and critical for chemo decision-making in node-negative/1-3 node patients. |
| ER+/HER2+ | Chemo + Dual HER2 Blockade (Trastuzumab + Pertuzumab) → Adjuvant Trastuzumab/Pertuzumab (1 yr) + ET. |
| Triple Negative (TNBC) / Pleomorphic High Grade | Chemotherapy (Anthracycline/Taxane based) +/- Immunotherapy (Pembrolizumab if PD-L1+). |
Endocrine Therapy Selection
- Premenopausal: Tamoxifen (5–10 yrs) ± Ovarian Function Suppression (OFS) if high risk. AI + OFS if high risk/intolerant to Tamoxifen.
- Postmenopausal: Aromatase Inhibitor (AI) (Letrozole, Anastrozole, Exemestane) for 5–10 years. Sequential Tamoxifen → AI or AI → Tamoxifen acceptable.
- Extended Therapy (Years 5–10): AI preferred postmenopausally. Decision based on risk of recurrence vs. toxicity (bone health, arthralgia, cardiovascular).
Bone Health
- Baseline DEXA scan before starting AI.
- Denosumab (60mg SC q6mo) or Zoledronic Acid (4mg IV q6mo) indicated for osteopenia (T-score < -1.5) or high fracture risk (FRAX), and adjuvant zoledronic acid considered for postmenopausal women to reduce bone recurrence (EBCTCG data).
Follow-Up & Survivorship
| Component | Frequency / Details |
|---|---|
| History & Physical | Every 3–6 mo (yrs 1–3), 6–12 mo (yrs 4–5), annually thereafter. Meticulous bilateral breast/chest wall/axillary/SCV exam. |
| Imaging (Ipsilateral/Contralateral) | Annual Mammography (+/- Tomosynthesis). Annual MRI strongly considered for first 2–5 years (high ipsilateral/contralateral risk), then individualized. Ultrasound as adjunct. |
| Lab Surveillance | No routine tumor markers (CA 15-3, CEA) or imaging (CT/Bone/PET) for asymptomatic patients. (ASCO/NCCN guidelines). |
| Endocrine Toxicity Mgmt | Arthralgias (exercise, acupuncture, switch AI, duloxetine), Bone health (DEXA q1–2yrs, Vit D/Calcium, Bisphosphonate/Denosumab), Vaginal atrophy (non-hormonal moisturizers, low-dose vaginal estrogen if oncologist approves), Cognitive/sexual health. |
| Cardiac Surveillance | Baseline ECHO/MUGA if received Anthracycline/Trastuzumab/Radiation (Left). Long-term surveillance per cardio-oncology guidelines. |
| Second Primary Risk | Colonoscopy (standard screening + CDH1 carriers need earlier/more frequent), Skin checks, Gynecologic exams. |
Prognosis & Outcomes
- Stage-for-Stage: Survival outcomes for classic ILC are comparable to or slightly better than IDC in the first 5–7 years (due to indolent biology, ER+).
- Late Recurrence: ILC has a higher risk of late recurrence (Years 5–20+) than IDC. The annual recurrence rate remains constant (~1–2%/yr) for decades. Extended endocrine therapy (10 years) is strongly supported.
- Contralateral Breast Cancer: Cumulative risk ~0.5–1% per year; higher than IDC population.
- Pleomorphic/Signet Ring Variants: Behave more aggressively; prognosis aligns more closely with high-grade IDC.
Special Populations
1. Hereditary Diffuse Gastric Cancer (HDGC) / CDH1 Mutation Carriers
- Lifetime Breast Cancer Risk: 40–55% (almost exclusively ILC).
- Management: Risk-reducing Bilateral Mastectomy is the standard recommendation (often age 30–40 or 5–10yrs before earliest family diagnosis).
- Screening (if declining surgery): Annual MRI + Mammogram starting age 30. Note: MRI sensitivity for early ILC in CDH1 carriers may be lower than for IDC in BRCA carriers.
- Gastric Risk: Prophylactic Total Gastrectomy recommended for confirmed CDH1 pathogenic variants (typically age 20–30).
2. Pregnancy-Associated Breast Cancer (PABC)
- ILC diagnosed in pregnancy behaves similarly to non-pregnant counterparts.
- Diagnosis: US first; Mammogram with shielding; MRI without Gadolinium (avoid contrast). Core biopsy safe.
- Treatment: Surgery (2nd/3rd trimester), Chemo (2nd/3rd trimester – Anthracycline/Taxane), No Endocrine Therapy / No HER2 therapy / No Radiation until postpartum.
3. Male Breast Cancer
- ILC is exceedingly rare in men (<2% of male breast cancer) due to rudimentary lobular development. IDC histology predominates.
Summary: Key Takeaways for the Clinician & Patient
- Think “Thickening,” Not “Lump”: Educate patients on the subtle clinical feel of ILC.
- Imaging Gap: Negative mammogram/US does not exclude ILC if clinical concern exists. MRI is the problem-solving tool.
- Biology is Favorable (Usually): ER+/HER2- = Endocrine sensitive. Genomic testing spares many chemotherapy.
- Surgery is Tricky: High re-excision rates; MRI staging reduces (but doesn’t eliminate) this. Clear margins (“no ink”) are the goal.
- The Long Game: Recurrence risk extends beyond 10 years. Adherence to 10 years of endocrine therapy is the single most impactful survivorship intervention.
- Metastatic Pattern is Unique: Screen for GI, Gyn, Peritoneal, Meningeal symptoms in follow-up.
- Genetics Matter: Test CDH1 in lobular histology + family history/early onset/bilateral. Cascade testing saves lives (gastric + breast).
References
- Arpino, G., Bardou, V.J., Clark, G.M. and Elledge, R.M. (2004) ‘Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome’, Breast Cancer Research, 6(3), pp. R149–R156.
- Blohmer, J.U. et al. (2022) ‘Invasive lobular carcinoma of the breast: special histological type with distinct clinical behavior and therapeutic implications’, Deutsches Ärzteblatt International, 119(15-16), pp. 257–264.
- Breast Cancer Research Foundation (BCRF) (2023) Invasive Lobular Carcinoma (ILC): A Distinct Disease. Available at: https://www.bcrf.org/blog/invasive-lobular-carcinoma-ilc-distinct-disease/ (Accessed: 15 October 2023).
- Chen, Z. et al. (2017) ‘Outcomes of invasive lobular carcinoma vs invasive ductal carcinoma: a SEER population-based study’, JAMA Surgery, 152(12), pp. 1129–1137.
- Cristofanilli, M. et al. (2005) ‘Invasive lobular carcinoma classic and variants: molecular characterization and clinical outcomes’, Clinical Cancer Research, 11(18), pp. 6742s–6748s.
- Dixon, J.M. et al. (2019) ‘Lobular neoplasia and invasive lobular carcinoma’, in Dixon and Jones’ Breast Disease. 4th edn. London: CRC Press, pp. 345–378.
- ETV/ESO Consensus Guidelines (2023) ‘Treatment of early breast cancer: highlights of the ESO-ESMO 6th European Consensus Conference (ECC 2023)’, Annals of Oncology, 34(10), pp. 963–978.
- Fisher, C.S. et al. (2021) ‘Metastatic patterns of invasive lobular carcinoma’, Journal of Clinical Oncology, 39(15_suppl), pp. 1051–1051.
- Giuliano, A.E. et al. (2023) ‘Breast Cancer—Version 4.2023, NCCN Clinical Practice Guidelines in Oncology’, Journal of the National Comprehensive Cancer Network, 21(5), pp. 516–541.
- MacGrogan, G. et al. (2019) ‘Histological variants of invasive lobular carcinoma of the breast’, Histopathology, 74(1), pp. 137–148.
- National Comprehensive Cancer Network (NCCN) (2023) NCCN Guidelines for Patients: Breast Cancer, Invasive. Plymouth Meeting, PA: NCCN.
- Pestalozzi, B.C. et al. (2008) ‘Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials’, Journal of Clinical Oncology, 26(18), pp. 3006–3014.
- Rakha, E.A. et al. (2010) ‘Invasive lobular carcinoma of the breast: a comprehensive review’, Histopathology, 56(2), pp. 211–228.
- Ross, D.S. et al. (2019) ‘Surveillance imaging for women with a personal history of breast cancer’, Radiology, 293(2), pp. 271–279.
- Sabel, M.S. et al. (2021) ‘Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer’, Annals of Surgical Oncology, 28(3), pp. 1115–1131.
- Slowik, A.D. et al. (2020) ‘Neoadjuvant endocrine therapy for ER+ breast cancer: a systematic review and meta-analysis’, Annals of Surgical Oncology, 27(11), pp. 4201–4213.
- Soslow, R.A. et al. (2022) ‘WHO Classification of Tumours: Breast Tumours’, IARC WHO Classification of Tumours, 5th edn., Vol. 2. Lyon: International Agency for Research on Cancer.
- Tan, P.S. et al. (2018) ‘CDH1 germline mutations in hereditary diffuse gastric cancer and lobular breast cancer: a meta-analysis’, Journal of Medical Genetics, 55(9), pp. 585–592.
- Van Seumeren, I. et al. (2020) ‘Magnetic resonance imaging for staging of invasive lobular carcinoma: a systematic review and meta-analysis’, European Radiology, 30(12), pp. 6621–6632.
- Yerushalmi, R. et al. (2011) ‘Invasive lobular carcinoma: a distinct disease entity?’ Current Oncology Reports, 13(1), pp. 38–44.